glp·helper
glphelper.com/semaglutide/idaho/nampa
GLP-1 receptor agonistFDA-approved December 2017 (Ozempic) · June 2021 (Wegovy)Rx · Subcutaneous injection (weekly) · oral tablet (Rybelsus, daily) · Once weekly (injectable)

Semaglutide® providers &
prescriptions in Nampa, ID

Verified Semaglutide providers in Nampa, ID. Checked against the NPI registry, sorted by waitlist, not by who pays us.[7]

city providers
23
as of today
median wait
8d
first visit
telehealth
71%
of providers
cash range
$25 to $1,150
monthly
§ 02Provider directory: Idaho
23 of 23 shown

Find a Semaglutide provider in Idaho.

Every entry is checked against the NPI registry and the Idaho medical board. Listings are ordered by current waitlist. The provider who can see you fastest appears first. We do not accept payment for placement.

Filter →
Type
Provider
City
Waitlist
Insurance
Browse by Idaho city · /semaglutide/idaho/{city}
§ 03Getting Semaglutide in Nampa
23 providers · Nampa, ID

How to get Semaglutide in Nampa.

23 GLP-1 prescribers and 7 local resource types are on record for Nampa, plus 2 nearby towns in the directory.

Prescribers in Nampa
23 prescribers
23 GLP-1 prescribers in Nampa, most listed as Family Medicine (11), Internal Medicine (10) and Internal Medicine, Endocrinology, Diabetes & Metabolism (1). Any Idaho-licensed physician, nurse practitioner, or PA can prescribe Semaglutide, over video or in person. The nearest towns on record are Meridian (28 providers) and Boise (30 providers).
Around the prescription in Nampa
7 listed nearby
6 dietitians, 3 nutritionists, 6 gyms, 6 fitness clubs, 5 trainers, 6 physiotherapists and 6 places to move are on record near Nampa.
Medicaid (weight loss)
Diabetes only
As of April 2026, Idaho Medicaid covers GLP-1s for diabetes but not for weight loss. Employer and private plans can still cover them; that is a plan-design choice, not a state rule.

Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm Idaho’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.

§ 04Medication factsheet
cited · last review 2026.05.19

The molecule in Ozempic, Rybelsus, and Wegovy. The brands differ in approved use and maximum dose.

Semaglutide is a once-weekly GLP-1 receptor agonist sold under three brand names by Novo Nordisk: Ozempic and Rybelsus for type 2 diabetes, and Wegovy for chronic weight management. It mimics a gut hormone that signals satiety to the brain and slows gastric emptying. The injectable forms share the same molecule; only the approved indication and maximum dose differ.[2][3]

In the STEP-1 obesity trial, adults without diabetes taking Wegovy (semaglutide 2.4 mg) lost a mean of 14.9% of body weight at 68 weeks versus 2.4% with placebo. In the SELECT trial, semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in adults with overweight or obesity and established cardiovascular disease but without diabetes.[1]

At a glanceMultiple (brand-specific)
Generic name
semaglutide
Drug class
GLP-1 receptor agonist
Manufacturer
Novo Nordisk
FDA approved
December 2017 (Ozempic) · June 2021 (Wegovy)
Approved use
Type 2 diabetes (Ozempic/Rybelsus) · chronic weight management (Wegovy)
Off-label use
Use outside the approved brand/indication is off-label
Administration
Subcutaneous injection (weekly) · oral tablet (Rybelsus, daily) · Once weekly (injectable)
Available doses
0.25 mg · 0.5 mg · 1 mg · 1.7 mg · 2.4 mg
Half-life
≈ 7 days
Pregnancy
Discontinue ≥ 2 months before a planned pregnancy

Community health · CDC

Weight & metabolic health in Idaho

Diagnosed diabetes reaches 8.7% of adults in Idaho.

of Idaho adults have obesity
32.7%
diagnosed diabetes
8.7%

Age-adjusted estimates for Idaho, community figures, not individual risk. CDC BRFSS 2024.

Estimate your weight losshair shedding during weight loss
§ 05Support around Semaglutide in Nampa
6 fitness clubs

The prescription is one part. Here is the rest, in Nampa.

Trials of semaglutide paired the drug with diet counseling and regular activity. Every name below is a real listing near Nampa, ID, ordered as the registry lists them, never by who pays us.

Fitness clubs and recreation centers

Fitness clubs and recreation centers run classes and pools, an easier start than a weight room.

Harward Recreation Center
REC CENTER
4.4 on Google · 1022 reviews
131 Constitution Way
Website
North Meridian Fit Body Boot Camp
FITNESS
5.0 on Google · 82 reviews
1511 W McMillan Rd
Website
Meridian Homecourt
REC CENTER
4.6 on Google · 81 reviews
936 Taylor Ave
Website
Redemption Boot Camp
FITNESS
5.0 on Google · 55 reviews
4123 Challenger Way
Website
TRUHiT Fitness Star
FITNESS
5.0 on Google · 43 reviews
50 N Seneca Springs Way
Website
Gold Standard Sim Sports
CLUB
4.4 on Google · 40 reviews
10627 Pipevine Dr
Website

Registered dietitians

A registered dietitian builds the food plan around your prescription. Call to ask about GLP-1 nutrition plans and insurance.

Cynthia Alvarez, RD, LD
RD
Registered dietitian
207 1St St S
Call 208-466-7869NPI 1235904814
Sia Argeanas, R.D. L.D
RD
Registered dietitian
824 S Diamond St
Call 208-514-2103NPI 1043401847
Alicia Barlow, MS, RD
RD
Registered dietitian
4300 E Flamingo Ave
Call 208-205-1000NPI 1982351003
Amber Beebe, RDN
RD
Registered dietitian
115 W Main St Ste 203
Call 208-381-8330NPI 1457042558
Stacy Beeson
RD
Registered dietitian
9850 W St Lukes Dr Ste 327
Call 208-331-1155NPI 1811310360
Teresa Chinn, RD
RD
Registered dietitian
1127 Caldwell Blvd
Call 208-465-4935NPI 1184388407
§ 06Clinical evidence
STEP 1 to 4 + SELECT (N = 17,604)

What the trials actually showed.

We summarize the STEP weight-management program, the SUSTAIN diabetes program, and the SELECT cardiovascular outcomes trial. Figures are means at each trial's primary endpoint.

STEP-1 randomized 1,961 adults with overweight or obesity (without diabetes) to semaglutide 2.4 mg or placebo for 68 weeks. Mean weight change was −14.9% with semaglutide versus −2.4% with placebo; 86% of treated patients lost ≥5% of body weight.[2]
STEP / SELECT endpoint table2.4 mg / 68 wk
Mean weight change (Wegovy 2.4 mg)
−14.9%
STEP-1, 68 wk vs −2.4% placebo[2]
Patients losing ≥5% body weight
86%
STEP-1, 2.4 mg[2]
Major adverse cardiac events
−20%
SELECT, HR 0.80[3]
HbA1c reduction (T2D)
−1.4 to −1.8%
SUSTAIN program[4]
Effect size varies with baseline characteristics and adherence. Individual response may differ materially.
average semaglutide weight loss →mapped to your starting weight
§ 07Safety & adverse events
from FDA label, sect. 6.1

Most side effects are gastrointestinal and resolve within weeks.

The most common adverse events in STEP trials were nausea (44%), diarrhea (30%), and vomiting (24%), more frequent at the 2.4 mg dose than at Ozempic doses, but typically transient.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[8]

Boxed warning. Boxed warning: risk of thyroid C-cell tumors. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Effect
Frequency
Severity
Note
Nausea
20 to 44%
mild
Most common; dose-dependent, usually eases after titration
Diarrhea
20 to 30%
mild
More frequent during dose escalation
Vomiting
16 to 24%
mild
Reduced by slower titration
Constipation
20 to 24%
mild
Abdominal pain
10%
moderate
Pancreatitis
<0.3%
serious
Discontinue if acute pancreatitis is suspected
Gallbladder disease
1.6 to 2.6%
serious
Cholelithiasis risk rises with rapid weight loss
Thyroid C-cell tumors
rodent data
boxed warning
Contraindicated with MTC or MEN-2 history
§ 08Cost & coverage, published, not gated
USD · monthly

Most directories hide the price. We don't.

Cash prices vary roughly 50× between the brand-name retail rate and a manufacturer savings card. The number you actually pay depends on your insurance plan, your diagnosis code, and which pharmacy fills the script. Here are the ranges, plainly.

Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk patient access program.

Cash, Wegovy (no insurance)
$1,300 to $1,400
per month
Brand-name retail average[6]
Cash, Ozempic (no insurance)
$950 to $1,150
per month
Brand-name retail average[6]
Commercial insurance (T2D)
$25 to $250
per month copay
Usually covered for diabetes with prior authorization
Commercial insurance (weight)
Often denied
Wegovy is on-label but frequently requires PA and is denied
Medicare Part D
$0 to $100
per month
T2D covered; weight-loss indication not covered by law[5]
Manufacturer savings card
as low as $0 to $25
per month
Commercial insurance only; eligibility limits apply
Updated weekly · last fetch 2026-05-18 04:00 UTCCost methodology →
Find Semaglutide providers in Idaho

NPI-verified Semaglutide (semaglutide) prescribers and clinics, ordered by availability, never by who pays us.

Semaglutide in other states

Find NPI-verified Semaglutide (semaglutide) doctors, clinics, and pharmacies in the states we cover, ordered by availability, never by who pays us.

Related GLP-1 research
§ 09Frequently asked: Semaglutide in Idaho

The questions people ask before they book.

Answers reviewed by the GLPHelper Medical Team. Citations link to primary sources, never marketing copy.

Yes. Semaglutide is the active molecule in all three Novo Nordisk products. Ozempic and Rybelsus are approved for type 2 diabetes; Wegovy is approved for chronic weight management at a higher maximum dose (2.4 mg/week). Insurers treat the brands as separate drugs.[1]